FY14 looks solid, too early to give guidance: Sun Pharma
Uday Baldota, Senior Vice President, Finance and Accounts at Sun Pharma, feels that FY14 will be a steady growth year with lots of big revenue opportunities. He talks about the 100 pending approvals from the US drug regulator, and also gives some idea about a potential acquisition.
